Patients with lung adenocarcinoma typically carry a mutation in the Epidermal Growth Factor Receptor (EGFR) gene, making them ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...

They also found EGFR in the active conformation and wondered why this conformation seemed to be favored when crystallized (Zhang et al. 2006). They found that by mutating a residue in the kinase ...

EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

For example, EGFR 19 deletions and EGFR L858R point mutations respond well to tyrosine kinase inhibitors (TKIs), which are also called EGFR inhibitors. Drugs that target the EGFR protein and block ...

More information: Shen Yon Toh et al, Therapeutic application of extracellular vesicular EGFR isoform D as a co-drug to ...

and are treated with a class of targeted drugs called “EGFR tyrosine kinase inhibitors” that suppress the unusual growth of ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...

locally advanced or metastatic non-squamous non-small cell lung cancer [NSCLC] who have progressed after treatment with a 3rd generation EGFR Tyrosine Kinase Inhibitor [TKI]. Such data from this ...

DelveInsight's "TAGRISSO Market Size, Forecast, and Market Insight Report" highlights the details around TAGRISSO, a kinase inhibitor of the EGFR, which binds irreversibly to certain mutant forms of ...